FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis

BACKGROUND: Doublets plus anti‐epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left‐sided RAS/BRAF wild‐type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI‐bevacizumab is superior to doublets plus bevacizumab independently from primar...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Pietrantonio, Filippo, Fucà, Giovanni, Rossini, Daniele, Schmoll, Hans‐Joachim, Bendell, Johanna C., Morano, Federica, Antoniotti, Carlotta, Corallo, Salvatore, Borelli, Beatrice, Raimondi, Alessandra, Marmorino, Federica, Niger, Monica, Boccaccino, Alessandra, Masi, Gianluca, Lonardi, Sara, Boni, Luca, de Braud, Filippo, Di Bartolomeo, Maria, Falcone, Alfredo, Cremolini, Chiara
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2021
Gaiak:
Gastrointestinal Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018298/
https://ncbi.nlm.nih.gov/pubmed/33336844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13642
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak